NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Crescendo Biologics Ltd.

Crescendo Biologics Ltd.

Private
CambridgeHealthcare & Life Scienceshttps://www.crescendobiologics.com/

Last Round

VC Round

Jul 24, 2023

Total Funding Raised

$179.71M

Company Overview

Crescendo Biologics Ltd. is a biotechnology company that develops novel, targeted T-cell enhancing therapeutics based on its proprietary Humabody® VH platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

biotechnologyoncology therapeuticsHumabodyantibody fragmentsdrug discoveryT-cell activationbiologicsheavy-chain-only antibodiessingle-domain antibodiesnanobodiestransgenic mouse platformtumor microenvironmentclinical-stage biotechmulti-specific antibodiespharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Crescendo Biologics Ltd. Comparables

Compare Crescendo Biologics Ltd. with similar companies based on industry and business-model similarity.

Crescendo Biologics Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Leveragen, Inc.
81%
Isogenica
80%
AbTherx, Inc.
79%

Crescendo Biologics Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 24, 2023
Corporate FundingJan 10, 2022
Series BApr 30, 2018
VC RoundDec 16, 2014
Series AApr 3, 2014
Series A
Dec 17, 2013

Key People

Founding team and executive leadership

Eric Rosenfeld

CEO

Executive Team

Crescendo Biologics Ltd. Investors

Notable investors and investment history

Crescendo Biologics Ltd. investors
InvestorRounds
Kreos CapitalVC Round
IP GroupVC Round, Series B
Andera PartnersVC Round, Series B
Kreos CapitalVC Round
UK Innovation & Science Seed FundSeed
Imperial InnovationsSeries A
Astellas Venture ManagementVC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 17, 2013

    $31M round led by Imperial Innovations and Touchstone Innovations.

Crescendo Biologics Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Crescendo Biologics Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Crescendo Biologics Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range10
Year Founded2009
Last FundingJul 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.